Donna Romero
Pharmaceuticals Professional
Donna L. Romero currently owns her own consulting company, Pharma-Vation Consulting, LLC. She received her Ph.D. from the University of Wisconsin-Madison from Professor Barry Trost. She has many years of experience in the pharmaceutical industry working for The Upjohn Company, Pharmacia, and Pfizer and consulting for the NIH Blueprint program and a variety of biotechnology companies such as Nimbus Discovery..
Donna Romero is the Head of IRAK4 Program at Nimbus Therapeutics and has more than 20 years of experience in drug discovery and development and pharmaceutical research management. She began her career at the Upjohn Company where she was the inventor of the non-nucleoside reverse transcriptase inhibitor Rescriptor® marketed for the treatment of HIV. Subsequently, Dr. Romero held project team leadership positions on the Cell Cycle and Bacterial Genomics Teams. She has broad experience leading and supervising cross-disciplinary drug discovery teams in multiple therapeutic areas in the Upjohn, Pharmacia, and Pfizer pharmaceutical companies. Since leaving Pfizer in 2007, where she was a Senior Director in Medicinal Chemistry, Dr. Romero has been an independent consultant working with a broad array of biotechnology companies and with the Spinal Muscular Atrophy Lead Development team for the NINDS and the NIH Blueprint project
links
https://www.linkedin.com/in/donna-romero-0a98a23
http://www.nimbustx.com/about-us/leadership
Summary
Specialties:Drug Discovery Project Leadership
Medicinal chemistry Strategy
Analog design and management of synthetic chemistry
Medicinal chemistry Strategy
Analog design and management of synthetic chemistry
Experience
Owner
Pharma-Vation Consulting, LLC
Pharma-Vation
Consulting provides drug discovery, medicinal chemistry, computational
and synthetic chemistry consulting services. Clients include NIH,
BioEnergenics, AzoRx, Michigan High Throughput Screening Center, Xenon,
Reaction Biology, and SW Michigan Life Sciences Venture Fund.
Director
Nimbus Discovery
Vice President of Chemical Sciences and Pharmaceutical Development
Emiliem, Inc.
Emiliem,
Inc. is a privately-held biopharmaceutical company focused on the
discovery and development of molecular targeted cancer therapies with
offices in the San Francisco Bay area and Kalamazoo, Michigan.
Senior Director
Pfizer Inc
•
Supervising ~35-45 medicinal chemists in the three therapeutic areas
(resourcing projects, mentoring, performance assessment, salary
administration, recruiting).
• Chemistry Leadership Team, Discovery Leadership Team, CVMED Therapeutic Area Chemistry Liason, CVMED Global Management Team, Hypertension and Thrombosis New Target Teams, Management consultant/mentor to program teams.
• Leading the “Improving Project Success” initiative - a Global cross-site, cross-functional team that is analyzing causes of project/target attrition in Discovery and recommending strategies to improve project survival
• St. Louis Point of Contact for the Global Pfizer Closed Loop (CLD) Project
• Led a cross-functional team to define and implement processes and infrastructure that improves the output of the drug discovery pipeline
• Built high-throughput autopurification & centralized sample logistics capabilities in StL
• Chemistry Leadership Team, Discovery Leadership Team, CVMED Therapeutic Area Chemistry Liason, CVMED Global Management Team, Hypertension and Thrombosis New Target Teams, Management consultant/mentor to program teams.
• Leading the “Improving Project Success” initiative - a Global cross-site, cross-functional team that is analyzing causes of project/target attrition in Discovery and recommending strategies to improve project survival
• St. Louis Point of Contact for the Global Pfizer Closed Loop (CLD) Project
• Led a cross-functional team to define and implement processes and infrastructure that improves the output of the drug discovery pipeline
• Built high-throughput autopurification & centralized sample logistics capabilities in StL
Director
Pharmacia
Supervised and mentored ~50 medicinal chemists in the Infectious Diseases and CNS therapeutic areas.
Bacterial Genome Team Leader. Led a multidisciplinary group of ~50 scientists in identifying essentail targets, developing screening strategies, triaging hits, and optimizing novel antibacterial lead templates.
Identified 5 novel inhibitors of 4 distinct antibacterial targets that proceeded to the chemistry optimization stage.
Devised "reverse genomics" strategy of mining the compound collection that led to the identification of a novel inhibitor of a well-established target (gyrase).
Managed external research collaborations with Cetek and NeoGenesis. Managed external CRO chemistry (Albany Molecular, and Pharmeco).
Bacterial Genome Team Leader. Led a multidisciplinary group of ~50 scientists in identifying essentail targets, developing screening strategies, triaging hits, and optimizing novel antibacterial lead templates.
Identified 5 novel inhibitors of 4 distinct antibacterial targets that proceeded to the chemistry optimization stage.
Devised "reverse genomics" strategy of mining the compound collection that led to the identification of a novel inhibitor of a well-established target (gyrase).
Managed external research collaborations with Cetek and NeoGenesis. Managed external CRO chemistry (Albany Molecular, and Pharmeco).
Education
Emory University
B.S., Chemistry and ComputerSci/Math
Activities and Societies: Varsity Tennis Team, Chorale, Help Line (volunteer counselor), undergraduate research
Additional Info
Advice for Contacting Donna
I
am interested in starting or becoming involved in existing biotech
business opportunities in the St. Louis area. I am available for virtual
Drug Discovery Project Leadership opportunities, i.e. leading and
managing drug discovery projects. I am also interested in general
medicinal chemistry and synthetic organic chemistry consulting
opportunities. Inquiries regarding potential career opportunities are
welcomed.
Recent Advances in the Discovery of Small Molecule Inhibitors of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) as a Therapeutic Target for Inflammation and Oncology Disorders
Miniperspective
† Nimbus Discovery, 25 First Street, Suite 404, Cambridge, Massachusetts 02141, United States
‡ Schrödinger Inc., 120 West Forty-Fifth Street, New York, New York 10036, United States
J. Med. Chem., 2015, 58 (1), pp 96–110
DOI: 10.1021/jm5016044
http://pubs.acs.org/doi/full/10.1021/jm5016044
//////////////
सुकून उतना ही देना प्रà¤ू, जितने से जिंदगी चल जाये। औकात बस इतनी देना, कि औरों का à¤à¤²ा हो जाये।
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO …..FOR BLOG HOME CLICK HERE
LIONEL MY SON
सुकून उतना ही देना प्रà¤ू, जितने से
जिंदगी चल जाये।
औकात बस इतनी देना,
कि औरों का à¤à¤²ा हो जाये।
Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL
//////////////
सुकून उतना ही देना प्रà¤ू, जितने से जिंदगी चल जाये। औकात बस इतनी देना, कि औरों का à¤à¤²ा हो जाये।
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO …..FOR BLOG HOME CLICK HERE
Join me on twitter
amcrasto@gmail.comLIONEL MY SON
He was only in first standard in school when I was hit by a deadly one
in a million spine stroke called acute transverse mylitis, it made me
90% paralysed and bound to a wheel chair, Now I keep him as my source of
inspiration and helping millions, thanks to millions of my readers who
keep me going and help me to keep my son happy
जिंदगी चल जाये।
औकात बस इतनी देना,
कि औरों का à¤à¤²ा हो जाये।
Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL
Susanta Samajdar, Ph.D., Research Director, Medicinal Chemistry, Aurigene Discovery Technologies Limited
